Definium Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
DFTX$35.39+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
| Common Shares | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts) | Shares | Amount | Additional Paid-In Capital | Accumulated OCI | Accumulated Deficit | Total |
| Balance, December 31, 2023 | 41,101,303 | $— | $367,991 | $343 | $(290,200) | $78,134 |
| Issuance of common shares and warrants, net of share issuance costs | 38,624,064 | — | 234,267 | — | — | 234,267 |
| Issuance of common shares upon settlement of restricted share unit ("RSU") awards, net of shares withheld for tax | 823,361 | — | (54) | — | — | (54) |
| Exchange of common shares for pre-funded warrants | (8,325,000) | — | — | — | — | — |
| Issuance of common shares upon conversion of loan principal | 748,129 | — | 3,000 | — | — | 3,000 |
| Exercise of 2022 USD Financing Warrants | 1,945,523 | — | 16,675 | — | — | 16,675 |
| Stock-based compensation expense | — | — | 16,913 | — | — | 16,913 |
| Exercise of stock options, net of shares withheld for tax | 183,383 | — | 716 | — | — | 716 |
| Net loss and comprehensive loss | — | — | — | 476 | (108,679) | (108,203) |
| Balance, December 31, 2024 | 75,100,763 | — | $639,508 | $819 | $(398,879) | $241,448 |
| Issuance of common shares, net of share issuance costs | 21,131,250 | — | 242,820 | — | — | 242,820 |
| Issuance of common shares under employee share purchase plan ("ESPP") | 66,165 | — | 412 | — | — | 412 |
| Issuance of common shares upon settlement of RSU awards, net of shares withheld for tax | 843,017 | — | — | — | — | — |
| Exercise of 2022 USD Financing Warrants | 886,346 | — | 9,703 | — | — | 9,703 |
| Exercise of pre-funded warrants | 324,972 | — | — | — | — | — |
| Issuance of common shares upon conversion of loan principal | 249,377 | — | 1,000 | — | — | 1,000 |
| Amortization of deferred ATM costs | — | — | (250) | — | — | (250) |
| Stock-based compensation expense | — | — | 20,096 | — | — | 20,096 |
| Exercise of stock options, net of shares withheld for exercise and tax | 174,375 | — | 625 | — | — | 625 |
| Net loss and comprehensive loss | — | — | — | 266 | (183,793) | (183,527) |
| Balance, December 31, 2025 | 98,776,265 | — | $913,914 | $1,085 | $(582,672) | $332,327 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.